This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yaspan, B. L. Articles by Smith, J. R. Search for Related Content PubMed PubMed Citation Articles by Yaspan, B. L. Articles by Smith, J. R.

Haplotype Analysis of CYP11A1 Identifies Promoter Variants Associated with Breast Cancer Risk

Departments of ¹ Cancer Biology, ² Medicine, and ³ Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine; ⁴ Medical Research Service, VA Tennessee Valley Healthcare System, Nashville, Tennessee; and ⁵ Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China

Requests for reprints: Jeffrey R. Smith, Department of Medicine, Vanderbilt University School of Medicine, 529 Light Hall, 2215 Garland Avenue, Nashville, TN 37232-0275. Phone: 615-936-2171; Fax: 615-936-2296; E-mail: jeffrey.smith{at}vanderbilt.edu and Wei Zheng, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN. Phone: 615-936-0682; Fax: 615-322-1754; E-mail: wei.zheng{at}vanderbilt.edu.

The CYP11A1 gene encodes the cholesterol side chain cleavage enzyme that catalyzes the initial and rate-limiting step of steroidogenesis. A large number of epidemiologic studies have implicated the duration and degree of endogenous estrogen exposure in the development of breast cancer in women. Here, we conduct a systematic investigation of the role of genetic variation of the CYP11A1 gene in breast cancer risk in a study of 1193 breast cancer cases and 1310 matched controls from the Shanghai Breast Cancer Study. We characterize the genetic architecture of the CYP11A1 gene in a Chinese study population. We then genotype tagging polymorphisms to capture common variation at the locus for tests of association. Variants designating a haplotype encompassing the gene promoter are significantly associated with both increased expression (P = 1.6e–6) and increased breast cancer risk: heterozygote age-adjusted odds ratio (OR), 1.51 [95% confidence interval (95% CI), 1.19–1.91]; homozygote age-adjusted OR, 2.94 (95% CI, 1.22–7.12), test for trend, P = 5.0e–5. Among genes controlling endogenous estrogen metabolism, CYP11A1 harbors common variants that may influence expression to significantly modify risk of breast cancer. [Cancer Res 2007;67(12):5673–82]

This article has been cited by other articles:

				J. P. Breyer, M. E. Sanders, D. C. Airey, Q. Cai, B. L. Yaspan, P. A. Schuyler, Q. Dai, F. Boulos, M. G. Olivares, K. M. Bradley, et al. Heritable Variation of ERBB2 and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1252 - 1258. [Abstract] [Full Text] [PDF]

				L. C. Sakoda, C. Blackston, J. A. Doherty, R. M. Ray, M. G. Lin, H. Stalsberg, D. L. Gao, Z. Feng, D. B. Thomas, and C. Chen Polymorphisms in Steroid Hormone Biosynthesis Genes and Risk of Breast Cancer and Fibrocystic Breast Conditions in Chinese Women Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1066 - 1073. [Abstract] [Full Text] [PDF]